Dyax is a biopharmaceutical company focused on developing and commercializing novel therapeutics for patients with rare diseases. We currently market a product for the treatment of acute attacks of HAE (to learn more, click here) and are advancing an investigational drug candidate for the prevention of HAE attacks (to learn more, click here). We are also applying our understanding of human monoclonal antibody development to expand our product pipeline to include disorders of thrombosis, immune dysregulation and vascular disease (to learn more, click here).
In addition to our internally developed products, we have broadly licensed our phage display technology and have a portfolio of product candidates being developed by our licensees. We call this portfolio the Licensing and Funded Research Portfolio (LFRP). The LFRP includes one approved product for which we receive royalties and several product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties.
|$ 34.20||-0.15 (0.44%)|
Day Low: 34.10
Nov 25, 2015